Jazz Pharmaceuticals PLC (NASDAQ:JAZZ – Get Free Report) CAO Patricia Carr sold 1,413 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $231.36, for a total transaction of $326,911.68. Following the transaction, the chief accounting officer owned 6,512 shares of the company’s stock, valued at $1,506,616.32. This represents a 17.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Jazz Pharmaceuticals Price Performance
Shares of NASDAQ JAZZ opened at $234.76 on Friday. The company has a market capitalization of $15.24 billion, a price-to-earnings ratio of 79.85, a PEG ratio of 0.43 and a beta of 0.38. The company has a current ratio of 1.78, a quick ratio of 1.58 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals PLC has a twelve month low of $128.80 and a twelve month high of $266.38. The firm has a 50-day moving average of $229.39 and a two-hundred day moving average of $217.74.
Jazz Pharmaceuticals (NASDAQ:JAZZ – Get Free Report) last issued its earnings results on Monday, November 2nd. The specialty pharmaceutical company reported ($3.88) earnings per share for the quarter, beating the consensus estimate of ($4.03) by $0.15. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $1.21 billion. Jazz Pharmaceuticals had a net margin of 4.37% and a return on equity of 16.55%. The firm’s revenue was up 10.4% on a year-over-year basis. During the same period in the previous year, the business earned $8.13 EPS. As a group, analysts expect that Jazz Pharmaceuticals PLC will post 10.88 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Jazz Pharmaceuticals
Key Jazz Pharmaceuticals News
Here are the key news stories impacting Jazz Pharmaceuticals this week:
- Positive Sentiment: Jazz beat quarterly estimates, reporting $1.24 billion in revenue versus roughly $1.21 billion expected, with revenue up 10.4% year over year. Coverage also reported that the company raised its 2026 revenue outlook to approximately $4.78 billion–$4.85 billion, helping reinforce the growth outlook. Q3 results and outlook
- Positive Sentiment: RBC, Barclays, Morgan Stanley and JPMorgan issued favorable commentary or raised price targets after the results. The analyst optimism adds support to the stock’s post-earnings momentum. Barclays price-target update
- Neutral Sentiment: CEO Renée Galá sold 1,000 shares under a pre-arranged Rule 10b5-1 plan and retained 140,394 shares. Director Bruce Cozadd also sold 6,000 shares under a pre-arranged plan, while CAO Patricia Carr sold 1,413 shares and retained 6,512. These sales may draw investor attention, but planned transactions are not necessarily a signal about near-term business prospects. Insider transaction coverage
Analysts Set New Price Targets
Several research analysts recently commented on JAZZ shares. Morgan Stanley increased their price target on Jazz Pharmaceuticals from $314.00 to $319.00 and gave the company an “overweight” rating in a research report on Tuesday. Piper Sandler boosted their price objective on shares of Jazz Pharmaceuticals from $301.00 to $310.00 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Robert W. Baird raised their price objective on Jazz Pharmaceuticals from $252.00 to $280.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 4th. Wall Street Zen downgraded Jazz Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Needham & Company LLC boosted their price objective on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday, August 26th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $293.45.
Check Out Our Latest Stock Analysis on JAZZ
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing medicines for neurological, sleep-related and oncology disorders. The company serves patients and healthcare providers in the United States and international markets, with products marketed through its commercial operations and partnerships.
Jazz’s sleep portfolio includes Xyrem and Xywav, which are used to treat certain symptoms associated with narcolepsy. Following its acquisition of GW Pharmaceuticals, the company also added Epidiolex, a cannabidiol-based treatment for specific forms of treatment-resistant epilepsy.
Featured Stories
- Five stocks we like better than Jazz Pharmaceuticals
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
- MarketBeat Week in Review – 11/2 – 11/6
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
